Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

Long-term haematologic relapse-free survival follow-up from a Phase 2 study of blinatumomab in B-lineage ALL with MRD.